Major trial gives hope to Motor Neurone Disease sufferers
Patients suffering from a devastating disease are being given fresh hope through an innovative trial being led by the Sheffield Institute for Translational Neuroscience (SITraN) and Sheffield Teaching Hospitals.
The trial uses a new device to see if it can help patients with Motor Neurone Disease (MND), a condition that leads to muscle weakness and ultimately death, to live for longer and with a better quality of life.
Patients with the disease, which affects around two in every 100,000 people in the United Kingdom, experience weakness of the limbs, have difficulty with speech, swallowing, and breathing. Weakness of breathing muscles including the diaphragm (the main breathing muscle), usually results in death within two to three years.
In the revolutionary trial patients with MND are having a device – called a diaphragm pacing (DP) system – implanted to help increase the strength of their main breathing muscle. Small electrodes are implanted into the diaphragm, while a small external stimulator delivers electric pulses, strengthening the muscle. Patients carry a small device that enables them to switch the pulses on and off.
The study, called DiPALS, is funded by the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme and the Motor Neurone Disease Association (MNDA), to a value of over £1.3m. It will compare use of the device with the standard treatment for MND, which involves providing the patient with ventilation through a mask. The trial will take place at five different sites across the country, and will see 108 patients taking part, with half receiving the device and half the standard treatment.
After 12 months, patients with the device can choose to stay with it or revert to standard treatment. It is hoped that the device will prove to have benefits that are not gained through standard treatment. For example, not all patients are able to tolerate standard treatment, as it can interfere with communication and eating, and the ventilator can restrict mobility. Use of the device could potentially provide patients with a better quality of life, and life span.
Dr Christopher McDermott, Senior Clinical Lecturer in Neurology at the University of Sheffield and Honorary Consultant Neurologist, who is leading the study, said: "It's excellent that we've been able to gain such generous funding to trial diaphragm pacing in a large-scale study. The technique has shown promise in our pilot series, and so we are pleased to have the opportunity to fully assess the devices and establish if they can provide benefits to patients.
"Treatments for breathing difficulties in MND have improved in recent years, but this trial will establish whether we can improve the quality of life and life expectancy of MND patients even further. We hope, if proven to be of benefit, that diaphragm pacing could become standard treatment in the NHS."
Patient Malcolm Chattle, 70, of Crookes, Sheffield was diagnosed with MND in 2006 and had the device implanted as part of a pilot version of the trial in 2009. He said: "The disease was making it difficult for me to breathe, and as a result I was having trouble sleeping. Having the device has really helped me to breathe and has improved my quality of life.
"The device means I can still walk quite a distance, and I can sleep much better. Using the device is very simple – I just have to switch it on at night. The staff have also been great and very helpful.
"I'm really pleased this trial is taking place, as it should help lots of patients in the future."
The trial will conclude in 2014, when all the results will be brought together.
Notes for Editors: The research will take place in NHS Hospital settings in Sheffield (Royal Hallamshire Hospital), Oxford (John Radcliffe Hospital), Newcastle upon Tyne (Royal Victoria Infirmary), Manchester (University Hospital of South Manchester and Salford Royal NHS Foundation Trust Hospital), Birmingham (University Hospitals Birmingham NHS Foundation Trust).
With nearly 25,000 students from 125 countries, the University of Sheffield is one of the UK's leading and largest universities. A member of the Russell Group, it has a reputation for world-class teaching and research excellence across a wide range of disciplines.
The University of Sheffield has been named University of the Year in the Times Higher Education Awards for its exceptional performance in research, teaching, access and business performance. In addition, the University has won four Queen's Anniversary Prizes (1998, 2000, 2002, 2007). These prestigious awards recognise outstanding contributions by universities and colleges to the United Kingdom's intellectual, economic, cultural and social life. Sheffield also boasts five Nobel Prize winners among former staff and students and many of its alumni have gone on to hold positions of great responsibility and influence around the world.
The University's research partners and clients include Boeing, Rolls Royce, Unilever, Boots, AstraZeneca, GSK, ICI, Slazenger, and many more household names, as well as UK and overseas government agencies and charitable foundations.
The University has well-established partnerships with a number of universities and major corporations, both in the UK and abroad. Its partnership with Leeds and York Universities in the White Rose Consortium has a combined research power greater than that of either Oxford or Cambridge.
For further information, please visit University of Sheffield
For further information please contact: Amy Pullan, Media Relations Officer, on 0114 2229859 or email email@example.com